Expression and potential application of histone deacetylase in prostate cancer
10.3760/cma.j.issn.1000-6702.2011.09.007
- VernacularTitle:组蛋白去乙酰化酶在前列腺癌组织中表达的意义
- Author:
Qilai LONG
;
Rui LIN
;
Yuanfeng YANG
;
Yanjun ZHU
;
Zhengwang ZHANG
;
Jianming GUO
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Carcinoma;
Histone deacetylase
- From:
Chinese Journal of Urology
2011;32(9):603-606
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the expression and activity of histone deacetylase (HDAC) in prostate cancer.Methodshe pathological samples of 37 cases of PCa were collected. The mean age of the patients was 73 (53 - 88 ) years, the preoperative t-PSA was 81.69 ( 3.13 - 2000 ) ng/ml, Gleason score: 13 cases were ≤7, 24 cases were ＞7. Twenty-seven cases of BPH were set as controls. The mean age of the BPH patients was 69 (52 - 84) years, the preoperative t-PSA was 10.93 ( 1.11 - 55.07 ) ng/ml.Western blotting and colorimetric Assay kits were used to determine the HDAC expression and activity. The difference of HDAC activity in benign prostatic hyperplasia and prostate cancer was statistically analyzed.The correlation of the HDAC expression level and values of PSA and Gleason score was also assessed.ResultsHDACs were over-expressed in most cases of prostate cancer, the expression rates were HDAC1 :57％, HDAC2: 68％, HDAC3: 84％ and HDAC4: 73％, respectively. The HDAC activity (P ＜0.05)was significantly different between the prostate cancer and benign prostatic hyperplasia groups. The expression level of HDAC did not correlate with the values of PSA and Gleason score.ConclusionsHDAC was highly expressed and strongly active in prostate cancer. The results suggest that HDAC might be a potential target for the management of prostate cancer patients.
